These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 24938439)

  • 1. Synergistic role of self-emulsifying lipids and nanostructured porous silica particles in optimizing the oral delivery of lovastatin.
    Rao S; Tan A; Boyd BJ; Prestidge CA
    Nanomedicine (Lond); 2014 Dec; 9(18):2745-59. PubMed ID: 24938439
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lyophilized silica lipid hybrid (SLH) carriers for poorly water-soluble drugs: physicochemical and in vitro pharmaceutical investigations.
    Yasmin R; Tan A; Bremmell KE; Prestidge CA
    J Pharm Sci; 2014 Sep; 103(9):2950-2959. PubMed ID: 24585389
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Porous Silica-Supported Solid Lipid Particles for Enhanced Solubilization of Poorly Soluble Drugs.
    Yasmin R; Rao S; Bremmell KE; Prestidge CA
    AAPS J; 2016 Jul; 18(4):876-85. PubMed ID: 27048207
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhancing the oral bioavailability of simvastatin with silica-lipid hybrid particles: The effect of supersaturation and silica geometry.
    Meola TR; Schultz HB; Peressin KF; Prestidge CA
    Eur J Pharm Sci; 2020 Jul; 150():105357. PubMed ID: 32446169
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pluronic-Functionalized Silica-Lipid Hybrid Microparticles: Improving the Oral Delivery of Poorly Water-Soluble Weak Bases.
    Rao S; Richter K; Nguyen TH; Boyd BJ; Porter CJ; Tan A; Prestidge CA
    Mol Pharm; 2015 Dec; 12(12):4424-33. PubMed ID: 26523928
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of lipophilic emulsifiers on the oral administration of lovastatin from nanostructured lipid carriers: physicochemical characterization and pharmacokinetics.
    Chen CC; Tsai TH; Huang ZR; Fang JY
    Eur J Pharm Biopharm; 2010 Mar; 74(3):474-82. PubMed ID: 20060469
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Silica encapsulated lipid-based drug delivery systems for reducing the fed/fasted variations of ziprasidone in vitro.
    Dening TJ; Rao S; Thomas N; Prestidge CA
    Eur J Pharm Biopharm; 2016 Apr; 101():33-42. PubMed ID: 26812284
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Silica-lipid hybrid (SLH) microcapsules: a novel oral delivery system for poorly soluble drugs.
    Tan A; Simovic S; Davey AK; Rades T; Prestidge CA
    J Control Release; 2009 Feb; 134(1):62-70. PubMed ID: 19013488
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Silica nanoparticles to control the lipase-mediated digestion of lipid-based oral delivery systems.
    Tan A; Simovic S; Davey AK; Rades T; Boyd BJ; Prestidge CA
    Mol Pharm; 2010 Apr; 7(2):522-32. PubMed ID: 20063867
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Supersaturated Silica-Lipid Hybrid Oral Drug Delivery Systems: Balancing Drug Loading and In Vivo Performance.
    Schultz HB; Kovalainen M; Peressin KF; Thomas N; Prestidge CA
    J Pharmacol Exp Ther; 2019 Sep; 370(3):742-750. PubMed ID: 30552294
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An oral delivery system for indomethicin engineered from cationic lipid emulsions and silica nanoparticles.
    Simovic S; Hui H; Song Y; Davey AK; Rades T; Prestidge CA
    J Control Release; 2010 May; 143(3):367-73. PubMed ID: 20079390
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Supersaturated silica-lipid hybrids (super-SLH): An improved solid-state lipid-based oral drug delivery system with enhanced drug loading.
    Schultz HB; Thomas N; Rao S; Prestidge CA
    Eur J Pharm Biopharm; 2018 Apr; 125():13-20. PubMed ID: 29277724
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Silica-lipid hybrid (SLH) versus non-lipid formulations for optimising the dose-dependent oral absorption of celecoxib.
    Tan A; Davey AK; Prestidge CA
    Pharm Res; 2011 Sep; 28(9):2273-87. PubMed ID: 21560021
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergistic role of solid lipid and porous silica in improving the oral delivery of weakly basic poorly water soluble drugs.
    Yasmin R; Rao S; Bremmell K; Prestidge C
    Eur J Pharm Sci; 2017 Jan; 96():508-514. PubMed ID: 27793717
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhancement of abiraterone acetate oral bioavailability by supersaturated-silica lipid hybrids.
    Schultz HB; Wignall AD; Thomas N; Prestidge CA
    Int J Pharm; 2020 May; 582():119264. PubMed ID: 32278053
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Silica-lipid hybrid (SLH) formulations enhance the oral bioavailability and efficacy of celecoxib: An in vivo evaluation.
    Nguyen TH; Tan A; Santos L; Ngo D; Edwards GA; Porter CJ; Prestidge CA; Boyd BJ
    J Control Release; 2013 Apr; 167(1):85-91. PubMed ID: 23353808
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of novel mesoporous nanomatrix-supported lipid bilayers for oral sustained delivery of the water-insoluble drug, lovastatin.
    Zhang Y; Zhang H; Che E; Zhang L; Han J; Yang Y; Wang S; Zhang M; Gao C
    Colloids Surf B Biointerfaces; 2015 Apr; 128():77-85. PubMed ID: 25731096
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dry hybrid lipid-silica microcapsules engineered from submicron lipid droplets and nanoparticles as a novel delivery system for poorly soluble drugs.
    Simovic S; Heard P; Hui H; Song Y; Peddie F; Davey AK; Lewis A; Rades T; Prestidge CA
    Mol Pharm; 2009; 6(3):861-72. PubMed ID: 19358600
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A safety, tolerability, and pharmacokinetic study of a novel simvastatin silica-lipid hybrid formulation in healthy male participants.
    Meola TR; Abuhelwa AY; Joyce P; Clifton P; Prestidge CA
    Drug Deliv Transl Res; 2021 Jun; 11(3):1261-1272. PubMed ID: 32918160
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhanced dissolution and oral bioavailability of nifedipine by spontaneous emulsifying powders: effect of solid carriers and dietary state.
    Weerapol Y; Limmatvapirat S; Jansakul C; Takeuchi H; Sriamornsak P
    Eur J Pharm Biopharm; 2015 Apr; 91():25-34. PubMed ID: 25615879
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.